As of May 28th, RudaCure Inc. was selected for the 产业通商资源部's (Announcement No. 2020-145, March 6, 2020) 2020 研发 Rediscovery Project new evaluation for the project titled [Development of source technology for 干眼症治疗药 using Rac1 inhibitor RCI001 for regulatory approval]. RudaCure is the lead institution, with detailed institutions Gil Medical Foundation and IP Darae Strategy Commercialization Center, with a total project budget of KRW 350 million per year. The company will spend the next year developing raw material 制药 production methods and standards and testing methods for RCI001.